ArticleBMC pharmacology & toxicology2025
Biochemical and histopathological investigation to study the impact of pyriproxyfen exposure on ovarian morphology and reproductive function in female rats.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPyriproxyfen (PYR) is a pyridine-based broad-spectrum insect growth regulator and pesticide which works as an analogue of juvenile hormone. Its exposure to aquatic animals and crops is linked with various hazardous effects on biological functions. We aimed to find the possible reprotoxic effects of pyriproxyfen in adult female Sprague-Dawley rats through histological and biochemical approaches.
methodsAdult female rats were assigned to four groups and were administered 0 mg/kg (Control), 62 mg/kg b.w, 124 mg/kg b.w, and 186 mg/kg b.w., of PYR dissolved in distilled water for 28 consecutive days. Body mass index, blood glucose levels, total protein concentration, lipid profile, ovarian histology and reproductive hormonal profiles were determined.
resultsThere were no significant changes in body weight due to PYR exposure; however, slight alterations in ovarian and uterine weights were noted in the treatment groups. The 186 mg/kg b.w. treatment significantly affected estrous cyclicity. Furthermore, a non-significant increase in total protein levels and a significant (p < 0.05) rise in triglyceride and total cholesterol levels were recorded. However, a significant decline in high-density lipids was recorded in the high-dose treatment group (186 mg/kg bw) as compared to the control. A notable reduction in plasma concentration of estradiol, progesterone, and cortisol levels was recorded between the control and all the treated groups. Ovarian histomorphological analysis showed distorted basal membranes, increased empty spaces, tissue decompaction, degenerate follicles, and disassembled epithelium in the high-dose treated group (186 mg/kg b.w).
conclusionOral administration of PYR in adult female rats leads to altered organ weights, disturbed normal estrous cycle, increased triglycerides and total cholesterol, reduced high-density lipids concentrations, and damaged ovarian architecture, affecting biochemical and reproductive function in female rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.